Several publications have delivered updates on Genmab's (CPSE:GMAB) valuation, focusing on recent share price movements and revenue growth. Genmab's blend of robust fundamentals and bullish technicals was highlighted, even as HC Wainwright lowered their stock price target due to the EPKINLY trial. Darzalex's growth apparently fuels a rally. Optimism, however, is tempered by unsuccessful cancer drug trials. Deutsche Bank sees upside in Genmab's oncology venture while the stock falls due to key endpoint misses in Phase 3 epcoritamab trials. An AI partnership with Anthropic fortifies Genmab's position, but mixed results from late-stage trials of their lymphoma drug induce a dip in shares. Genmab's acquisition of Merus shares has induced faith in the company's pipeline potential. With this, their stock hits new highs and is back in the favorable limelight for investors. Although some drug development discontinuity is noted, others like Darzalex continue driving growth. Overall, Genmab's recent partnerships and acquisitions shape their 2025 value positively.
Genmab Stocks News Analytics from Mon, 02 Jun 2025 07:00:00 GMT to Sat, 24 Jan 2026 23:09:30 GMT - Rating 6 - Innovation 8 - Information 8 - Rumor 7
